BREAKTHROUGH THERAPIES FOR
PULMONARY ARTERIAL HYPERTENSION
Apaxen is a privately-held biotechnology company whose mission is to bring innovative treatments to patients in a wide range of therapeutic indications related to chronic inflammation, with a primary focus in pulmonary arterial hypertension (PAH) and other deadly pulmonary diseases.
Latest News
Apaxen appoints Graham K. Dixon as Chairman and prepares for clinical testing of its lead inflammasome inhibitor
Belgian biotech Apaxen appoints Bart Wuurman as CEO
TEAM
MANAGEMENT TEAM
DISEASES
Pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a rare, chronic and life-threatening disease characterized by an abnormal and progressive increase in blood pressure in the small pulmonary arteries leading ultimately to right heart failure and death.
Idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a rare, chronic and life-threatening disease in which the tissues of the lungs become progressively thick and stiff.
SCIENCE
PIPELINE
Apaxen has a robust pipeline of products at discovery and preclinical stages of development for the treatment of diseases associated with chronic inflammation. Pulmonary arterial hypertension (PAH) and other deadly pulmonary diseases are the primarily targeted indications.
R&D STRATEGY
APaxen’s R&D is focused on research and development of breakthrough therapeutics for the treatment of diseases associated with chronic inflammation, with a primary focus in pulmonary arterial hypertension (PAH) and other deadly pulmonary diseases, including IPF and PH-IPF.
MIF as a therapeutic target in PAH
Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine that plays a key role in several chronic inflammatory diseases
MFC-1040
Apaxen’s lead compound, MFC-1040, is a novel, first-in-class, orally bioavailable and selective small molecule inhibitor of pleiotropic pro-inflammatory cytokine MIF (macrophage migration inhibitory factor).
PARTNERSHIP
Apaxen has established strategic collaborations and partnerships with main academic research centers specialized in pulmonary arterial hypertension (PAH). We are looking for additional partnership opportunities regarding our preclinical programs in the field of chronic inflammation.
INVESTORS
On July 2019, Apaxen has raised €3.3 million in a Series A equity funding round that gathered four funds: Theodorus, Sambrinvest, Innovation Fund, Financière Spin-off Luxembourgeoise along with members of “Be Angels”, one of the most important Business Angels network in Europe, while Theodorus was the lead investor.